newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

  • Aligos Therapeutics reported Q3 2026 financial results & business progress on November 6, 2026.
  • The Phase 2 B-SUPREME study of pevifoscorvir sodium is enrollment complete with 131 participants in the HBeAg+ cohort & 114 in the HBeAg- cohort.
  • Topline data for both pevifoscorvir sodium cohorts is expected in late Q3 2027.
  • Partner Amoytop advanced ASO ALG-170675 into Phase 1 clinical studies in China & is funding development costs for the region.
  • Cash, cash equivalents, & investments totaled $31.1 million as of September 30, 2026, providing sufficient funding into Q1 2027.
  • Net loss for the three months ended September 30, 2026, was $21.9 million ($2.09 per share), compared to $31.5 million ($3.04 per share) in 2025.
  • R&D expenses decreased to $18.9 million in Q3 2026 from $23.9 million in 2025 due to reduced third-party costs for the pevifoscorvir sodium trial.
  • G&A expenses increased to $5.9 million in Q3 2026 from $5.2 million in 2025 primarily due to higher legal & related expenses.
  • Revenue from licensing agreements was $39,000 for the quarter, while total revenue including customer sales reached $3.2 million.
  • The change in fair value of 2023 common warrants resulted in $0.2 million income for the quarter, contrasting with a $4.2 million loss in 2025.